miRNA-199a-5p/SLC2A1 axis regulates glucose metabolism in non-small cell lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Lung cancer is a leading cause of cancer morbidity and mortality worldwide.
• MicroRNAs (miRNAs) are non-coding RNA molecules with significant roles in cancer development and progression.
• Aberrant miRNA expression is implicated in various cancers, including non-small cell lung cancer (NSCLC).

Purpose of the Study:

• To investigate the role of miR-199a-5p in non-small cell lung cancer (NSCLC).
• To identify the molecular targets of miR-199a-5p in NSCLC.
• To explore the potential of miR-199a-5p as a therapeutic agent for NSCLC.

Main Methods:

• Quantitative real-time PCR to assess miR-199a-5p expression in NSCLC sera.
• Cell proliferation, migration, and cell cycle assays in NSCLC cell lines.
• Western blotting and luciferase reporter assays to validate SLC2A1 as a direct target of miR-199a-5p.

Main Results:

• miR-199a-5p was significantly downregulated in NSCLC sera samples.
• Overexpression of miR-199a-5p suppressed NSCLC cell proliferation, migration, and induced cell cycle arrest.
• SLC2A1 (glucose transporter 1, GLUT1) was identified as a direct target of miR-199a-5p.
• Downregulation of SLC2A1 mimicked the effects of miR-199a-5p, inhibiting proliferation and migration while promoting apoptosis.
• miR-199a-5p was shown to inhibit glucose metabolism in NSCLC by targeting SLC2A1.

Conclusions:

• miR-199a-5p plays a crucial role in suppressing NSCLC progression by targeting SLC2A1 and inhibiting glucose metabolism.
• The miR-199a-5p/SLC2A1 axis represents a potential therapeutic target for NSCLC treatment.
• Restoring miR-199a-5p levels could offer a novel strategy for clinical intervention in NSCLC.